Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Wirkungsfaktor Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Chen, Wei Prof. Dr. (1) Daniel, Peter Prof. Dr. (1) Falcke, Martin Prof. Dr. (1) Janz, Martin Dr. (4) Kammertöns, Thomas Dr. (2) Kopp, Joachim Dr. (1) Landthaler, Markus Prof. Dr. (1) Mathas, Stephan Dr. (4) Pezzutto, Antonio Prof. Dr. (1) Rajewsky, Nikolaus Prof. Dr. (1) Selbach, Matthias Prof. Dr. (7) Uckert, Wolfgang Prof. Dr. (2) Willimsky, Gerald Dr. (1) Wolf, Jana Prof. Dr. (2) (-) Blankenstein, Thomas Prof. Dr. (5) (-) Kirchner, Marieluise Dr. (1) (-) Leisegang, Matthias Prof. Dr. rer. nat. (1) (-) Molekulare Immunologie und Gentherapie (5) (-) Proteom Dynamik (1) Zelluläre Neurowissenschaften (11) 1992 (4) 1993 (7) 1994 (5) 1995 (8) 1997 (9) 1998 (9) 1999 (2) 2000 (8) 2001 (5) 2002 (5) 2003 (9) 2004 (8) 2005 (10) 2006 (2) 2007 (5) 2008 (5) 2009 (2) 2010 (7) (-) 2011 (6) 2012 (8) 2013 (11) 2015 (4) 2016 (4) 2017 (7) 2019 (7) 2020 (1) 2021 (4) 2022 (7) 2023 (5) 2024 (2) 6 Ergebnisse: Active Filter: Blankenstein, Thomas Prof. Dr.Kirchner, Marieluise Dr.Leisegang, Matthias Prof. Dr. rer. nat.Molekulare Immunologie und Gentherapie Proteom Dynamik2011 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein 01. November 2011 / Eur J Immunol Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors J. Charo C. Perez C. Buschow A. Jukica M. Czeh T. Blankenstein 01. November 2011 / Biospektrum In vivo-SILAC: Quantitative Analyse der Proteomdynamik [In vivo-SILAC: Quantitative analysis of proteome dynamics] M. Kirchner M. Selbach 15. Januar 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens 01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto 13. Dezember 2011 / Canc Cell Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer K. Anders C. Buschow A. Herrmann A. Milojkovic C. Loddenkemper T. Kammertoens P. Daniel H. Yu J. Charo T. Blankenstein
28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein
01. November 2011 / Eur J Immunol Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors J. Charo C. Perez C. Buschow A. Jukica M. Czeh T. Blankenstein
01. November 2011 / Biospektrum In vivo-SILAC: Quantitative Analyse der Proteomdynamik [In vivo-SILAC: Quantitative analysis of proteome dynamics] M. Kirchner M. Selbach
15. Januar 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto
13. Dezember 2011 / Canc Cell Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer K. Anders C. Buschow A. Herrmann A. Milojkovic C. Loddenkemper T. Kammertoens P. Daniel H. Yu J. Charo T. Blankenstein